Talbot Jeffery N, Geffert Laura M, Jorvig Jessica E, Goldstein Ruben I, Nielsen Cienna L, Wolters Nicholas E, Amos Mary Ellen, Munro Caitlin A, Dallman Elizabeth, Mereu Maddalena, Tanda Gianluigi, Katz Jonathan L, Indarte Martín, Madura Jeffry D, Choi Hailey, Leak Rehana K, Surratt Christopher K
Research Center on Substance Abuse and Depression, College of Pharmacy, Roseman University of Health Sciences, 11 Sunset Way, Henderson, NV 89014, USA.
Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA.
Pharmacol Biochem Behav. 2016 Nov-Dec;150-151:22-30. doi: 10.1016/j.pbb.2016.08.007. Epub 2016 Aug 26.
Rational design of lead compounds targeting monoamine transporters (MATs) is critical to developing novel therapeutics to treat psychiatric disorders including depression and substance abuse. A 3-D dopamine transporter (DAT) computer model was used to virtually screen a commercially available small molecule library for high DAT affinity drug-like compounds. One hit, coded "MI-4", inhibited human dopamine, norepinephrine, and serotonin transporters in vitro. In vivo administration in mice induced robust, dose-dependent antidepressant-like behaviors in learned helplessness models (tail suspension and forced swim tests). Moreover, chronic administration (21day, 10mg/kg, bid) reduced drinking latencies comparable to fluoxetine (10mg/kg, bid) in the novelty-induced hypophagia test, which requires chronic treatment to produce antidepressant-like effects. MI-4 (10mg/kg, bid) produced rapid (three-day) antidepressant-like effects in the social avoidance test following 10days of social defeat stress. Unlike ketamine, chronic administration of MI-4 increased social interaction scores while improving resiliency to the mood-altering effects of stress to over 70%. Importantly, MI-4 exhibited minimal abuse liability in behavioral and neurological models (conditioned place preference and dopamine in vivo microdialysis). MI-4 was found to be Ro-25-6981, an ifenprodil analog and reputed NMDA antagonist. The data suggest that Ro-25-6981, previously known for rapid-acting glutamatergic antidepressant actions, may also functionally inhibit monoamine reuptake and produces sustained antidepressant effects in vivo. This demonstrates, as proof of principle, the viability of combining these mechanisms to produce rapid and sustained antidepressant-like effects. Overall, these findings suggest MAT computational model-based virtual screening is a viable method for identifying antidepressant lead compounds of unique scaffold.
合理设计靶向单胺转运体(MATs)的先导化合物对于开发治疗包括抑郁症和药物滥用在内的精神疾病的新型疗法至关重要。使用三维多巴胺转运体(DAT)计算机模型对市售小分子文库进行虚拟筛选,以寻找具有高DAT亲和力的类药物化合物。筛选出的一个命中化合物,编码为“MI-4”,在体外可抑制人多巴胺、去甲肾上腺素和5-羟色胺转运体。在小鼠体内给药可在习得性无助模型(悬尾和强迫游泳试验)中诱导出强烈的、剂量依赖性的抗抑郁样行为。此外,在新奇诱导的摄食减少试验中,慢性给药(21天,10mg/kg,每日两次)可缩短饮水潜伏期,效果与氟西汀(10mg/kg,每日两次)相当,该试验需要慢性治疗才能产生抗抑郁样效果。在经历10天社会挫败应激后的社会回避试验中,MI-4(10mg/kg,每日两次)产生了快速(三天)的抗抑郁样效果。与氯胺酮不同,MI-4的慢性给药增加了社会互动得分,同时将对应激情绪改变作用的恢复力提高到70%以上。重要的是,MI-4在行为和神经模型(条件性位置偏爱和体内多巴胺微透析)中表现出最小的滥用倾向。发现MI-4是Ro-25-6981,一种艾芬地尔类似物,也是著名的NMDA拮抗剂。数据表明,以前以快速起效的谷氨酸能抗抑郁作用而闻名的Ro-25-6981,在体内也可能功能性抑制单胺再摄取并产生持续的抗抑郁作用。这作为原理证明,证明了结合这些机制产生快速和持续抗抑郁样效果的可行性。总体而言,这些发现表明基于MAT计算模型的虚拟筛选是识别具有独特骨架的抗抑郁先导化合物的可行方法。